A carregar...
Anti-Vascular Endothelial Growth Factor Therapies and Cardiovascular Toxicity: What Are the Important Clinical Markers to Target?
BACKGROUND. Therapies targeting vascular endothelial growth factor (VEGF) are associated with hypertension, cardiotoxicity, and thromboembolic events. METHODS. All prospective phase I–III clinical trials published up to December 2008 of approved anti-VEGF therapies (bevacizumab, sunitinib, sorafenib...
Na minha lista:
| Main Authors: | , , , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
AlphaMed Press
2010
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3227935/ https://ncbi.nlm.nih.gov/pubmed/20139170 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2009-0252 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|